{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:29Z","timestamp":1786980149494,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010374","name":"Stichting Blindenhulp","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010374","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009954","name":"Stichting MaculaFonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009954","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Retina Nederland Onderzoek Fonds"},{"DOI":"10.13039\/501100010373","name":"Stichting Blinden-Penning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010302","name":"Algemene Nederlandse Vereniging ter voorkoming van Blindheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010318","name":"Landelijke Stichting voor Blinden en Slechtzienden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010372","name":"Rotterdamse Stichting Blindenbelangen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010372","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stichting Leids Oogheelkundig Ondersteuningsfonds"},{"DOI":"10.13039\/501100010331","name":"Stichting voor Ooglijders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001717","name":"Universiteit Leiden","doi-asserted-by":"publisher","award":["the Gisela Thier Fellowship"],"award-info":[{"award-number":["the Gisela Thier Fellowship"]}],"id":[{"id":"10.13039\/501100001717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VENI grant"],"award-info":[{"award-number":["VENI grant"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Comparing anatomic and functional efficacy and safety of primary treatment with either half-dose photodynamic therapy (PDT) or oral eplerenone, or crossover treatment in chronic central serous chorioretinopathy patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After the SPECTRA trial baseline visit, patients were randomized to either half-dose PDT or eplerenone and received crossover treatment if persistent subretinal fluid (SRF) on optical coherence tomography (OCT) was present at first follow-up (at 3\u00a0months). Presence of SRF and best-corrected visual acuity (BCVA) was evaluated at 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of the 90 patients evaluated at 12\u00a0months, complete SRF resolution was present on OCT in 43\/48 (89.6%) of patients who were primarily randomized to half-dose PDT and in 37\/42 (88.1%) who were primarily randomized to eplerenone. Out of the 42 patients that were primarily randomized to eplerenone, 35 received crossover treatment with half-dose PDT. The BCVA improved significantly more at 12\u00a0months in patients who had received primary half-dose PDT as compared to the primary eplerenone group (p\u2009=\u20090.030).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Twelve months after baseline visit, most patients treated with half-dose PDT (either primary or crossover treatment) still had complete SRF resolution. The long-term BCVA in patients who receive primary half-dose PDT is better than in patients in whom PDT is delayed due to initial eplerenone treatment with persistent SRF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-022-05836-x","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T23:26:30Z","timestamp":1665098790000},"page":"659-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3"],"prefix":"10.1007","volume":"261","author":[{"given":"Helena M. A.","family":"Feenstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elon H. C.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"van Rijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roula","family":"Tsonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselie M. H.","family":"Diederen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel B.","family":"Hoyng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier O.","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camiel J. F.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"5836_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82\u2013118. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"5836_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/s0002-9394(14)70531-8","volume":"121","author":"C Prunte","year":"1996","unstructured":"Prunte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121:26\u201334. https:\/\/doi.org\/10.1016\/s0002-9394(14)70531-8","journal-title":"Am J Ophthalmol"},{"issue":"Pt 3","key":"5836_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/eye.1995.63","volume":"9","author":"FC Piccolino","year":"1995","unstructured":"Piccolino FC, Borgia L, Zinicola E, Zingirian M (1995) Indocyanine green angiographic findings in central serous chorioretinopathy. Eye (Lond) 9(Pt 3):324\u2013332. https:\/\/doi.org\/10.1038\/eye.1995.63","journal-title":"Eye (Lond)"},{"key":"5836_CR4","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, Sivaprasad S, Querques G, Downes SM, Fauser S, Hoyng CB, Piccolino FC, Chhablani JK, Lai TYY, Lotery AJ, Larsen M, Holz FG, Freund KB, Yannuzzi LA, Boon CJF (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.07.003","journal-title":"Prog Retin Eye Res"},{"key":"5836_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/IAE.0000000000001966","volume":"39","author":"EHC van Dijk","year":"2019","unstructured":"van Dijk EHC, Schellevis RL, Breukink MB, Mohabati D, Dijkman G, Keunen JEE, Yzer S, den Hollander AI, Hoyng CB, de Jong EK, Boon CJF (2019) Familial central serous chorioretinopathy. Retina 39:398\u2013407. https:\/\/doi.org\/10.1097\/IAE.0000000000001966","journal-title":"Retina"},{"key":"5836_CR6","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1167\/iovs.15-17343","volume":"56","author":"MB Breukink","year":"2015","unstructured":"Breukink MB, Schellevis RL, Boon CJ, Fauser S, Hoyng CB, den Hollander AI, de Jong EK (2015) Genomic copy number variations of the complement component C4B gene are associated with chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 56:5608\u20135613. https:\/\/doi.org\/10.1167\/iovs.15-17343","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5836_CR7","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1097\/IAE.0000000000002333","volume":"39","author":"D Mohabati","year":"2019","unstructured":"Mohabati D, Schellevis RL, van Dijk EHC, Altay L, Fauser S, Hoyng CB, De Jong EK, Boon CJF, Yzer S (2019) Genetic risk factors in acute central serous chorioretinopathy. Retina 39:2303\u20132310. https:\/\/doi.org\/10.1097\/IAE.0000000000002333","journal-title":"Retina"},{"key":"5836_CR8","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1097\/IAE.0000000000002682","volume":"40","author":"D Mohabati","year":"2020","unstructured":"Mohabati D, Schellevis RL, van Dijk EHC, Fauser S, den Hollander AI, Hoyng CB, De Jong EK, Yzer S, Boon CJF (2020) Genetic risk factors in severe, nonsevere and acute phenotypes of central serous chorioretinopathy. Retina 40:1734\u20131741. https:\/\/doi.org\/10.1097\/IAE.0000000000002682","journal-title":"Retina"},{"key":"5836_CR9","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1167\/iovs.19-26781","volume":"60","author":"RL Schellevis","year":"2019","unstructured":"Schellevis RL, Altay L, Kalisingh A, Mulders TWF, Sitnilska V, Hoyng CB, Boon CJF, Groenewoud JMM, de Jong EK, den Hollander AI (2019) Elevated steroid hormone levels in active chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 60:3407\u20133413. https:\/\/doi.org\/10.1167\/iovs.19-26781","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5836_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/bjophthalmol-2018-312431","volume":"103","author":"MG Ersoz","year":"2019","unstructured":"Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M (2019) Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients. Br J Ophthalmol 103:725\u2013729. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312431","journal-title":"Br J Ophthalmol"},{"key":"5836_CR11","doi-asserted-by":"publisher","unstructured":"Brinks J, van Dijk EHC, Klaassen I, Schlingemann RO, Kielbasa SM, Emri E, Quax PHA, Bergen AA, Meijer OC, Boon CJF (2021) Exploring the choroidal vascular labyrinth and its molecular and structural roles in health and disease. Prog Retin Eye Res 87:100994 https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100994","DOI":"10.1016\/j.preteyeres.2021.100994"},{"key":"5836_CR12","doi-asserted-by":"publisher","first-page":"100955","DOI":"10.1016\/j.preteyeres.2021.100955","volume":"84","author":"EHC van Dijk","year":"2021","unstructured":"van Dijk EHC, Boon CJF (2021) Serous business: delineating the broad spectrum of diseases with subretinal fluid in the macula. Prog Retin Eye Res 84:100955. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100955","journal-title":"Prog Retin Eye Res"},{"key":"5836_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.oret.2020.07.026","volume":"4","author":"Chhablani J, Cohen FB, Central Serous Chorioretinopathy International G","year":"2020","unstructured":"Chhablani J, Cohen FB, Central Serous Chorioretinopathy International G (2020) Multimodal imaging-based central serous chorioretinopathy classification. Ophthalmol Retina 4:1043\u20131046. https:\/\/doi.org\/10.1016\/j.oret.2020.07.026","journal-title":"Ophthalmol Retina"},{"key":"5836_CR14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S174573","volume":"12","author":"D Mohabati","year":"2018","unstructured":"Mohabati D, van Dijk EH, van Rijssen TJ, de Jong EK, Breukink MB, Martinez-Ciriano JP, Dijkman G, Hoyng CB, Fauser S, Yzer S, Boon CJ (2018) Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy. Clin Ophthalmol (Auckland, NZ) 12:2167\u20132176. https:\/\/doi.org\/10.2147\/OPTH.S174573","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"5836_CR15","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/IAE.0000000000002683","volume":"40","author":"D Mohabati","year":"2020","unstructured":"Mohabati D, Hoyng CB, Yzer S, Boon CJF (2020) Clinical characteristics and outcome of posterior cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 40:1742\u20131750. https:\/\/doi.org\/10.1097\/IAE.0000000000002683","journal-title":"Retina"},{"key":"5836_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2018.12.048","volume":"126","author":"S Mrejen","year":"2019","unstructured":"Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, Yannuzzi NA, Patel S, Chen KC, Yu S, Stoffels G, Spaide RF, Freund KB, Yannuzzi LA (2019) Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmol 126:576\u2013588. https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.048","journal-title":"Ophthalmol"},{"key":"5836_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2147\/OPTH.S160956","volume":"12","author":"D Mohabati","year":"2018","unstructured":"Mohabati D, van Rijssen TJ, van Dijk EH, Luyten GP, Missotten TO, Hoyng CB, Yzer S, Boon CJ (2018) Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol (Auckland, NZ) 12:1061\u20131070. https:\/\/doi.org\/10.2147\/OPTH.S160956","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"5836_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OPTH.S115685","volume":"11","author":"MB Breukink","year":"2017","unstructured":"Breukink MB, Dingemans AJM, den Hollander AI, Keunen JEE, MacLaren RE, Fauser S, Querques G, Hoyng CB, Downes SM, Boon CJF (2017) Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol (Auckland, NZ) 11:39\u201346. https:\/\/doi.org\/10.2147\/OPTH.S115685","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"5836_CR19","doi-asserted-by":"publisher","unstructured":"van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmol 125(10):1547\u20131555. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.021","DOI":"10.1016\/j.ophtha.2018.04.021"},{"key":"5836_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2020.04.007","volume":"216","author":"TJ van Rijssen","year":"2020","unstructured":"van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, MacLaren RE, Downes SM, Fauser S, Boon CJF, Hoyng CB (2020) Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial. Am J Ophthalmol 216:80\u201389. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.007","journal-title":"Am J Ophthalmol"},{"key":"5836_CR21","doi-asserted-by":"publisher","unstructured":"van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, Keunen JEE, MacLaren RE, Hoyng CB, Downes SM, Fauser S, Boon CJF (2021) Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy micropulse laser. Acta Ophthalmol 99(7):805\u2013811. https:\/\/doi.org\/10.1111\/aos.14775","DOI":"10.1111\/aos.14775"},{"key":"5836_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, investigators Vt (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(19)32981-2","journal-title":"Lancet"},{"key":"5836_CR23","doi-asserted-by":"publisher","unstructured":"van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF (2021) Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol 233:101\u2013110. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.020.","DOI":"10.1016\/j.ajo.2021.06.020"},{"key":"5836_CR24","doi-asserted-by":"publisher","unstructured":"Feenstra HMA, van Dijk EHC, van Rijssen TJ, Tsonaka R, Diederen RMH Schlingemann RO, Hoyng CB, Boon CJF (2022) Crossover to half-dose photodynamic therapy or eplerenone in chronic central serous chorioretinopathy patients (SPECS). Ophthalmol Retina 6(10):930\u2013938. https:\/\/doi.org\/10.1016\/j.oret.2022.04.014","DOI":"10.1016\/j.oret.2022.04.014"},{"key":"5836_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","volume":"233","author":"TJ van Rijssen","year":"2021","unstructured":"van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF (2021) Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol 233:101\u2013110. https:\/\/doi.org\/10.1016\/j.ajo.2021.06.020","journal-title":"Am J Ophthalmol"},{"key":"5836_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","volume":"22","author":"RH Loo","year":"2002","unstructured":"Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19\u201324. https:\/\/doi.org\/10.1097\/00006982-200202000-00004","journal-title":"Retina"},{"key":"5836_CR27","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/IAE.0b013e31822bf6b1","volume":"31","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T (2011) One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 31:1921\u20131927. https:\/\/doi.org\/10.1097\/IAE.0b013e31822bf6b1","journal-title":"Retina"},{"key":"5836_CR28","doi-asserted-by":"publisher","unstructured":"Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM (2021) Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res 86:100973. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100973","DOI":"10.1016\/j.preteyeres.2021.100973"},{"key":"5836_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4","journal-title":"Eye (Lond)"},{"key":"5836_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40123-020-00250-0","volume":"9","author":"EHC van Dijk","year":"2020","unstructured":"van Dijk EHC, van Rijssen TJ, Subhi Y, Boon CJF (2020) Photodynamic therapy for chorioretinal diseases: a practical approach. Ophthalmol Ther 9:329\u2013342. https:\/\/doi.org\/10.1007\/s40123-020-00250-0","journal-title":"Ophthalmol Ther"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05836-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T06:39:45Z","timestamp":1678084785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5836"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05836-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"11 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Institutional Review Board Committee approval was obtained from all participating centers before the start of the study. Ethics approval was obtained from the medical ethical committee of Leiden University Medical Center (NL59158.058.16).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}